Fukumoto M - Search Results

1

KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer.

Nakayama N, Nakayama K, Yeasmin S, Ishibashi M, Katagiri A, Iida K, Fukumoto M, Miyazaki K. Nakayama N, et al. Among authors: fukumoto m. Br J Cancer. 2008 Dec 16;99(12):2020-8. doi: 10.1038/sj.bjc.6604783. Epub 2008 Nov 18. Br J Cancer. 2008. PMID: 19018267 Free PMC article.

2

Genetic classification of ovarian carcinoma based on microsatellite analysis: relationship to clinicopathological features and patient survival.

Huan Z, Nakayama K, Nakayama N, Ishibashi M, Yeasmin S, Katagiri A, Purwana IN, Iida K, Maruyama R, Fukumoto M, Miyazaki K. Huan Z, et al. Among authors: fukumoto m. Oncol Rep. 2008 Mar;19(3):775-81. Oncol Rep. 2008. PMID: 18288415

3

A BTB/POZ gene, NAC-1, a tumor recurrence-associated gene, as a potential target for Taxol resistance in ovarian cancer.

Ishibashi M, Nakayama K, Yeasmin S, Katagiri A, Iida K, Nakayama N, Fukumoto M, Miyazaki K. Ishibashi M, et al. Among authors: fukumoto m. Clin Cancer Res. 2008 May 15;14(10):3149-55. doi: 10.1158/1078-0432.CCR-07-4358. Clin Cancer Res. 2008. PMID: 18483383

4

Allelic loss at 19q12 and Xq11-12 predict an adverse clinical outcome in patients with mucinous ovarian tumours of low malignant potential.

Nakayama K, Takebayashi Y, Hata K, Fujiwaki R, Iida K, Fukumoto M, Miyazaki K. Nakayama K, et al. Among authors: fukumoto m. Br J Cancer. 2004 Mar 22;90(6):1204-10. doi: 10.1038/sj.bjc.6601681. Br J Cancer. 2004. PMID: 15026802 Free PMC article.

5

Prognostic value of overexpression of p53 in human ovarian carcinoma patients receiving cisplatin.

Nakayama K, Takebayashi Y, Nakayama S, Hata K, Fujiwaki R, Fukumoto M, Miyazaki K. Nakayama K, et al. Among authors: fukumoto m. Cancer Lett. 2003 Mar 31;192(2):227-35. doi: 10.1016/s0304-3835(02)00686-9. Cancer Lett. 2003. PMID: 12668287

6

Allelotypes as potential prognostic markers in ovarian carcinoma treated with cisplatin-based chemotherapy.

Nakayama S, Nakayama K, Takebayashi Y, Hata K, Fujiwaki R, Fukumoto M, Miyazaki K. Nakayama S, et al. Among authors: fukumoto m. Int J Mol Med. 2003 May;11(5):621-5. Int J Mol Med. 2003. PMID: 12684700

7

The proliferative activity of ovarian tumors of low malignant potential differs from that of ovarian carcinoma.

Nakayama K, Takebayashi Y, Hata K, Fujiwaki R, Iida K, Fukumoto M, Miyazaki K. Nakayama K, et al. Among authors: fukumoto m. Anticancer Res. 2003 Nov-Dec;23(6C):4657-62. Anticancer Res. 2003. PMID: 14981910

8

Expression of the thymidine phosphorylase gene in epithelial ovarian cancer.

Hata K, Kamikawa T, Arao S, Tashiro H, Katabuchi H, Okamura H, Fujiwaki R, Miyazaki K, Fukumoto M. Hata K, et al. Among authors: fukumoto m. Br J Cancer. 1999 Apr;79(11-12):1848-54. doi: 10.1038/sj.bjc.6690294. Br J Cancer. 1999. PMID: 10206303 Free PMC article.

9

Expression of TP and TIE2 genes in normal ovary with corpus luteum and in ovarian cancer: correlation with ultrasound-derived peak systolic velocity.

Hata K, Fujiwaki R, Nakayama K, Fukumoto M, Miyazaki K. Hata K, et al. Among authors: fukumoto m. Mol Hum Reprod. 2000 Apr;6(4):319-23. doi: 10.1093/molehr/6.4.319. Mol Hum Reprod. 2000. PMID: 10729313

10

Expression of thymidine phosphorylase in epithelial ovarian cancer: correlation with angiogenesis, apoptosis, and ultrasound-derived peak systolic velocity.

Hata K, Fujiwaki R, Maede Y, Nakayama K, Fukumoto M, Miyazaki K. Hata K, et al. Among authors: fukumoto m. Gynecol Oncol. 2000 Apr;77(1):26-34. doi: 10.1006/gyno.1999.5651. Gynecol Oncol. 2000. PMID: 10739687

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

752 results

Search Page

Filters